PubRank

Steven A Narod

Author PubWeight™ 393.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007 16.79
2 Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014 8.49
3 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002 8.09
4 Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006 6.73
5 Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010 6.01
6 Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004 5.85
7 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004 5.38
8 Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010 4.51
9 Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013 4.35
10 Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007 4.25
11 Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006 4.09
12 Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003 3.96
13 A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010 3.86
14 Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004 3.86
15 RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007 3.63
16 Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005 3.44
17 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013 3.42
18 Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2005 3.26
19 PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst 2013 3.15
20 Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007 2.97
21 Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: a descriptive study. Plast Reconstr Surg 2004 2.88
22 Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008 2.78
23 Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005 2.70
24 Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2008 2.65
25 Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 2014 2.60
26 Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2013 2.53
27 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004 2.51
28 Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006 2.49
29 A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 2008 2.43
30 Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006 2.41
31 Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 2007 2.41
32 Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013 2.39
33 Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004 2.25
34 Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol 2011 2.21
35 Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2009 2.20
36 Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011 2.19
37 Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 2011 2.17
38 Assessing individual risk for prostate cancer. J Clin Oncol 2007 2.13
39 International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008 2.13
40 The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 2011 2.09
41 Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst 2012 2.06
42 The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009 2.01
43 Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 2007 2.00
44 Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011 1.94
45 Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007 1.89
46 Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012 1.81
47 Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 1.78
48 Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet 2012 1.77
49 Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 2013 1.73
50 A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 2006 1.71
51 Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol 2010 1.70
52 Population based study of long-term rates of surgery for urinary incontinence after radical prostatectomy for prostate cancer. J Urol 2012 1.66
53 LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res 2011 1.64
54 A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004 1.60
55 Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat 2008 1.59
56 Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008 1.57
57 Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 2002 1.57
58 Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer 2006 1.53
59 Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol 2013 1.52
60 Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005 1.50
61 Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer 2005 1.48
62 Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2012 1.48
63 Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 2012 1.46
64 Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009 1.39
65 Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003 1.38
66 Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 2009 1.37
67 Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 2013 1.36
68 A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 2006 1.34
69 Hereditary ovarian cancer in Poland. Int J Cancer 2003 1.30
70 Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 2002 1.27
71 The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005 1.27
72 A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 2005 1.27
73 Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 2013 1.26
74 The role of reexcision for positive margins in optimizing local disease control after breast-conserving surgery for cancer. Breast J 2006 1.25
75 Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 2004 1.25
76 Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009 1.25
77 Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 2006 1.25
78 Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. Cancer 2009 1.24
79 Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci U S A 2002 1.23
80 Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010 1.21
81 A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer. Cancer Res 2005 1.21
82 Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014 1.20
83 RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res 2010 1.20
84 Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 2005 1.20
85 Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol 2008 1.19
86 Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 2002 1.17
87 On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2010 1.17
88 Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. Cancer 2009 1.17
89 Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol 2003 1.16
90 Familial risks of esophageal cancer among the Turkmen population of the Caspian littoral of Iran. Int J Cancer 2006 1.15
91 Significant proportion of breast and/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer 2004 1.14
92 Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling. J Med Genet 2007 1.14
93 The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2006 1.14
94 Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2006 1.14
95 Alcohol and risk of breast cancer. JAMA 2011 1.11
96 BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl) 2012 1.11
97 Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2011 1.11
98 Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2012 1.10
99 BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005 1.09
100 Re: Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst 2015 1.09
101 Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol 2007 1.08
102 BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 2002 1.06
103 The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer 2011 1.06
104 Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res 2008 1.06
105 Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res 2011 1.05
106 Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006 1.05
107 A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 2010 1.04
108 Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res 2009 1.04
109 Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis 2008 1.04
110 The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hered Cancer Clin Pract 2005 1.04
111 Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev 2006 1.03
112 The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One 2011 1.03
113 Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer 2008 1.02
114 Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 2006 1.02
115 Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. Breast Cancer Res Treat 2008 1.02
116 The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 2005 1.02
117 Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006 1.01
118 Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res 2009 1.01
119 ARHGDIA: a novel gene implicated in nephrotic syndrome. J Med Genet 2013 1.01
120 Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int J Cancer 2002 1.01
121 BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 2008 1.01
122 Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol Biomarkers Prev 2003 0.99
123 A low selenium level is associated with lung and laryngeal cancers. PLoS One 2013 0.99
124 Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 2013 0.99
125 The 3020insC allele of NOD2 predisposes to early-onset breast cancer. Breast Cancer Res Treat 2005 0.99
126 New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther 2011 0.98
127 Changes in psychosocial functioning 1 year after mastectomy alone, delayed breast reconstruction, or immediate breast reconstruction. Ann Surg Oncol 2011 0.98
128 A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 2002 0.98
129 The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev 2007 0.98
130 The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 2013 0.98
131 Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy. Clin Cancer Res 2006 0.98
132 Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003 0.98
133 Androgens and breast cancer. Steroids 2011 0.98
134 Fertility in women with BRCA mutations: a case-control study. Fertil Steril 2009 0.98
135 Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. Breast Cancer Res Treat 2008 0.97
136 Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 2003 0.97
137 A prospective study of breast cancer risk in relatives of BRCA1/BRCA2 mutation carriers. J Med Genet 2007 0.97
138 The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate 2013 0.97
139 Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 2010 0.97
140 Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 2012 0.96
141 Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest 2008 0.96
142 Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer 2004 0.96
143 A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 2004 0.95
144 Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med 2007 0.95
145 Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2005 0.95
146 Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 2008 0.95
147 Towards a dietary prevention of hereditary breast cancer. Cancer Causes Control 2005 0.95
148 Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alpha-hydroxyestrogen metabolites. Mol Genet Metab 2005 0.95
149 Is mammography adequate for screening women with inherited BRCA mutations and low breast density? Cancer Epidemiol Biomarkers Prev 2008 0.94
150 Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev 2002 0.94
151 MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2011 0.94
152 Candidate gene association study of esophageal squamous cell carcinoma in a high-risk region in Iran. Cancer Res 2009 0.94
153 The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2005 0.94
154 The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 2009 0.94
155 Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014 0.93
156 Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004 0.93
157 Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study. Cancer Res 2008 0.93
158 Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol 2010 0.92
159 Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2011 0.92
160 Germline RAP80 mutations and susceptibility to breast cancer. Breast Cancer Res Treat 2008 0.92
161 Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat 2015 0.91
162 BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol 2011 0.91
163 Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev 2011 0.91
164 The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. Cancer Causes Control 2015 0.91
165 The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer 2013 0.91
166 Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2005 0.91
167 Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidemiol Biomarkers Prev 2005 0.91
168 Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol 2012 0.91
169 Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. Hered Cancer Clin Pract 2011 0.90
170 Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 2002 0.90
171 Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat 2013 0.90
172 Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res Treat 2013 0.90
173 Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer 2008 0.90
174 Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. J Clin Oncol 2010 0.90
175 The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum Genet 2007 0.90
176 Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10. Cancer Res 2013 0.89
177 Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum Genet 2011 0.89
178 Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review. Maturitas 2011 0.89
179 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 0.89
180 BRCA1 mutations and colorectal cancer in Poland. Fam Cancer 2010 0.89
181 A common nonsense mutation of the BLM gene and prostate cancer risk and survival. Gene 2013 0.89
182 Multiple primary cancers as a guide to heritability. Int J Cancer 2014 0.89
183 A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res Treat 2007 0.89
184 Height, weight, BMI and ovarian cancer survival. Gynecol Oncol 2012 0.88
185 Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2007 0.88
186 A BRCA1 mutation in Native North American families. Hum Mutat 2002 0.88
187 Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J 2013 0.88
188 Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast Cancer Res Treat 2008 0.87
189 The rs1447295 and DG8S737 markers on chromosome 8q24 and cancer risk in the Polish population. Eur J Cancer Prev 2010 0.87
190 Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Breast Cancer Res Treat 2008 0.87
191 CHEK2 mutations and HNPCC-related colorectal cancer. Int J Cancer 2010 0.87
192 CDKN2A-positive breast cancers in young women from Poland. Breast Cancer Res Treat 2006 0.87
193 DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 2007 0.87
194 Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. Cancer Causes Control 2010 0.87
195 BRCA1 and BRCA2 families and the risk of skin cancer. Fam Cancer 2010 0.86
196 A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res 2014 0.86
197 Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Hum Mutat 2009 0.86
198 BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families. Fam Cancer 2006 0.86
199 The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. Breast Cancer Res Treat 2011 0.86
200 Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women. BMC Cancer 2008 0.86
201 Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 2007 0.86
202 Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Res Treat 2005 0.86
203 The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer. Breast Cancer Res Treat 2012 0.86
204 Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat 2007 0.86
205 Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes. J Med Genet 2011 0.86
206 BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies. Genet Test 2008 0.86
207 Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005 0.85
208 The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 2012 0.85
209 Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control 2003 0.84
210 Predictors of quality of life in women with a bilateral prophylactic mastectomy. Breast J 2005 0.84
211 The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 2011 0.84
212 Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev 2011 0.84
213 Mutation screening using fluorescence multiplex denaturing gradient gel electrophoresis (FMD): detecting mutations in the BRCA1 gene. Nat Protoc 2006 0.84
214 Impact of boost radiation in the treatment of ductal carcinoma in situ: a population-based analysis. Int J Radiat Oncol Biol Phys 2013 0.84
215 Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. Cancer Epidemiol Biomarkers Prev 2007 0.84
216 Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. Breast Cancer Res Treat 2014 0.83
217 Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. PLoS One 2010 0.83
218 Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res Treat 2013 0.83
219 Re: On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003 0.83
220 Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines. Cancer Epidemiol Biomarkers Prev 2003 0.83
221 Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1. Gynecol Oncol 2008 0.83
222 A fluorescent multiplex-DGGE screening test for mutations in the BRCA1 gene. Genet Test 2006 0.83
223 The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat 2013 0.82
224 Direct-to-patient BRCA1 testing: the Twoj Styl experience. Breast Cancer Res Treat 2006 0.82
225 CHEK2-positive breast cancers in young Polish women. Clin Cancer Res 2006 0.82
226 The impact of having a sister diagnosed with breast cancer on cancer-related distress and breast cancer risk perception. Cancer 2013 0.82
227 CHEK2 mutation and hereditary breast cancer. J Clin Oncol 2006 0.82
228 A common missense variant in BRCA2 predisposes to early onset breast cancer. Breast Cancer Res 2005 0.81
229 Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecol Oncol 2010 0.81
230 Folate and breast cancer: what about high-risk women? Cancer Causes Control 2012 0.81
231 BRCA mutations in Italian breast/ovarian cancer families. Eur J Hum Genet 2002 0.81
232 BARD1 and breast cancer in Poland. Breast Cancer Res Treat 2007 0.81
233 Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Fam Cancer 2015 0.81
234 Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 2011 0.81
235 Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. Can J Urol 2006 0.81
236 Prophylactic bilateral mastectomy: patterns of practice. Cancer 2002 0.81
237 Genetic heterogeneity of 8q24 region in susceptibility to cancer. J Natl Cancer Inst 2009 0.80
238 Time to reconsider subcutaneous mastectomy for breast-cancer prevention? Lancet Oncol 2005 0.80
239 Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecol Oncol 2009 0.80
240 Common variation in Nemo-like kinase is associated with risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2012 0.80
241 Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy. J Urol 2006 0.80
242 Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. Gynecol Oncol 2010 0.79
243 Variation in patterns of practice in diagnosing screen-detected prostate cancer. BJU Int 2004 0.79
244 Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett 2008 0.79
245 The relationship between bilateral oophorectomy and plasma hormone levels in postmenopausal women. Horm Cancer 2014 0.79
246 Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. Breast Cancer Res Treat 2014 0.79
247 Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2014 0.79
248 Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer. PLoS One 2009 0.79
249 The presence of prostate cancer at biopsy is predicted by a number of genetic variants. Int J Cancer 2013 0.79
250 Identification of patients at high risk of psychological distress after BRCA1 genetic testing. Genet Test Mol Biomarkers 2009 0.78
251 [Descriptive epidemiology and molecular genetics of hereditary breast cancer in Costa Rica]. Rev Biol Trop 2012 0.78
252 A BRCA1 mutation is not associated with increased indicators of oxidative stress. Clin Breast Cancer 2008 0.78
253 The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003 0.78
254 Re: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 2003 0.78
255 The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J 2011 0.78
256 Low-risk Genes and Multi-organ Cancer Risk in the Polish Population. Hered Cancer Clin Pract 2006 0.78
257 The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. Eur J Cancer Prev 2015 0.77
258 Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone. Hered Cancer Clin Pract 2013 0.77
259 International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Ann Surg Oncol 2013 0.77
260 Retracted Risk factors for ovarian cancers with and without microsatellite instability. Int J Gynecol Cancer 2013 0.77
261 Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Mol Nutr Food Res 2014 0.77
262 Risk factors for ovarian cancers with and without microsatellite instability. Int J Gynecol Cancer 2014 0.77
263 Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer. Anticancer Res 2012 0.77
264 Breast cancer prevention in women with a BRCA1 or BRCA2 mutation. Open Med 2007 0.77
265 Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. Cancer Causes Control 2012 0.77
266 A prospective study of mastectomy patients with and without delayed breast reconstruction: long-term psychosocial functioning in the breast cancer survivorship period. J Surg Oncol 2014 0.77
267 A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet. Hered Cancer Clin Pract 2006 0.76
268 Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'. BMC Cancer 2014 0.76
269 The effect of oral 3,3'-diindolylmethane supplementation on the 2:16α-OHE ratio in BRCA1 mutation carriers. Fam Cancer 2015 0.76
270 Breast tissue organochlorine levels and metabolic genotypes in relation to breast cancer risk Canada. Cancer Causes Control 2004 0.76
271 Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers. Obesity (Silver Spring) 2012 0.76
272 Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States. Breast Cancer Res Treat 2014 0.76
273 Method of cooking and risk of breast cancer in the Philippines. Cancer Causes Control 2006 0.76
274 Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? Breast Cancer Res Treat 2015 0.76
275 Should all women with breast cancer be tested for BRCA mutations at the time of diagnosis? J Clin Oncol 2011 0.75
276 Ovarian cancer survival by tumor dominance, a surrogate for site of origin. Cancer Causes Control 2015 0.75
277 Supplementary imaging for breast cancer screening in high-risk women. JAMA 2012 0.75
278 Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers. Fam Cancer 2013 0.75
279 Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. Hered Cancer Clin Pract 2005 0.75
280 Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2015 0.75
281 Risk of ovarian cancer in breast-cancer patients with a family history of either. Lancet 2003 0.75
282 Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. Am J Epidemiol 2016 0.75
283 Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations. Breast J 2009 0.75
284 Re: Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 2003 0.75
285 Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet 2016 0.75
286 Tamoxifen chemoprevention and cardiac disease. J Clin Oncol 2011 0.75
287 BRCA1 founder mutations compared to ovarian cancer in Belarus. Fam Cancer 2014 0.75
288 Genetics of endometrial cancer. Fam Cancer 2014 0.75
289 Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2015 0.75
290 Familial association of laryngeal, lung, stomach and early-onset breast cancer. Breast Cancer Res Treat 2007 0.75
291 Male to female ratio among offspring of BRCA1 mutation carriers. Breast Cancer Res Treat 2005 0.75
292 DCIS and Breast Cancer: Challenging the Paradigm. Ann Surg 2017 0.75
293 A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. Int J Gynecol Cancer 2017 0.75
294 Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. Breast Cancer Res Treat 2014 0.75
295 Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation. J Nutrigenet Nutrigenomics 2015 0.75
296 BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer. Int J Gynecol Cancer 2017 0.75